Bio-Techne Partners with Refeyn to Transform Antibody Analysis in Biotech Research

Earlier this week, Bio-Techne (TECH) and Refeyn announced a transformative partnership aimed at revolutionizing the characterization process of bispecific antibodies and biosimilars in biotechnology research. The collaboration merges Bio-Techne’s advanced MauriceFlex™ icIEF fractionation technology with Refeyn's cutting-edge TwoMP mass photometry platform, providing researchers with a powerful integrated workflow. This innovation significantly enhances the efficiency and accuracy of analyzing these complex molecules, which is crucial in the rapidly evolving field of biopharmaceutical development.

The new system introduced through this partnership allows for detailed characterization of charge and size variants within a streamlined timeframe of just four hours. This efficiency marks a substantial improvement over traditional methods, which often extend analysis times and incur greater operational complexities. By enabling direct correlation between charge heterogeneity, molecular weight, and aggregation, the integrated system offers researchers high-fidelity results from nanogram-level samples. This capability accelerates the research process, thus optimizing timelines in drug development, a critical factor as the industry faces growing demands for faster and more effective therapeutics.

Bio-Techne’s dedication to enhancing biotechnology workflows through innovative technologies aligns perfectly with Refeyn’s mission of advancing mass photometry solutions for molecular analysis. This partnership not only promises to provide more accurate insights into the properties of bispecific antibodies and biosimilars but also reinforces the importance of collaboration in the biotech space to foster improved drug development strategies. Through these advancements, Bio-Techne and Refeyn are poised to set new industry standards, ultimately benefiting broader healthcare outcomes by enabling the development of more sophisticated biopharmaceutical products.

In related developments, Bio-Techne continues to expand its suite of technologies that support researchers in various fields, emphasizing its commitment to innovation within the life sciences sector. With the integration of advanced technologies, the company aims to enhance capabilities in protein analysis and characterization, ensuring that scientists have access to the best tools available for their work.

Overall, this partnership reflects a significant step towards establishing a more efficient and dependable framework for the analysis of biopharma products, potentially leading to accelerated timelines in bringing new treatments to market.